{"transactions":[{"id":1384172,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-10-18T22:51:26.000Z","date":"2024-10-17","kind":"exercise","planned":false,"acquired":false,"shares":237,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"Immediately exercisable."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F6","text":"The securities are directly held by Mr. Lichter."}],"balance_after":6072,"derivative":{"exercise_price":39.8,"expiration_date":"2027-07-19","underlying":"Common Stock","underlying_shares":237},"source":{"system":"sec-edgar","filing":"0001415889-24-025436","document":"form4-10182024_101021.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":33,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924025436/form4-10182024_101021.xml","form_type":"4"}},{"id":1384171,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-10-18T22:51:26.000Z","date":"2024-10-17","kind":"exercise","planned":false,"acquired":false,"shares":348,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"Immediately exercisable."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F6","text":"The securities are directly held by Mr. Lichter."}],"balance_after":9142,"derivative":{"exercise_price":13.22,"expiration_date":"2027-07-19","underlying":"Common Stock","underlying_shares":348},"source":{"system":"sec-edgar","filing":"0001415889-24-025436","document":"form4-10182024_101021.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":32,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924025436/form4-10182024_101021.xml","form_type":"4"}},{"id":1384170,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-10-18T22:51:26.000Z","date":"2024-10-17","kind":"exercise","planned":false,"acquired":false,"shares":348,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"Immediately exercisable."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F6","text":"The securities are directly held by Mr. Lichter."}],"balance_after":9142,"derivative":{"exercise_price":10.73,"expiration_date":"2027-07-19","underlying":"Common Stock","underlying_shares":348},"source":{"system":"sec-edgar","filing":"0001415889-24-025436","document":"form4-10182024_101021.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":31,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924025436/form4-10182024_101021.xml","form_type":"4"}},{"id":1384169,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-10-18T22:51:26.000Z","date":"2024-10-17","kind":"exercise","planned":false,"acquired":false,"shares":836,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"Immediately exercisable."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F6","text":"The securities are directly held by Mr. Lichter."}],"balance_after":21940,"derivative":{"exercise_price":17,"expiration_date":"2027-07-19","underlying":"Common Stock","underlying_shares":836},"source":{"system":"sec-edgar","filing":"0001415889-24-025436","document":"form4-10182024_101021.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":30,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924025436/form4-10182024_101021.xml","form_type":"4"}},{"id":1384168,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-10-18T22:51:26.000Z","date":"2024-10-16","kind":"exercise","planned":false,"acquired":false,"shares":1407,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"Immediately exercisable."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F6","text":"The securities are directly held by Mr. Lichter."}],"balance_after":6309,"derivative":{"exercise_price":39.8,"expiration_date":"2027-07-19","underlying":"Common Stock","underlying_shares":1407},"source":{"system":"sec-edgar","filing":"0001415889-24-025436","document":"form4-10182024_101021.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":29,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924025436/form4-10182024_101021.xml","form_type":"4"}},{"id":1384167,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-10-18T22:51:26.000Z","date":"2024-10-16","kind":"exercise","planned":false,"acquired":false,"shares":2070,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"Immediately exercisable."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F6","text":"The securities are directly held by Mr. Lichter."}],"balance_after":9490,"derivative":{"exercise_price":13.22,"expiration_date":"2027-07-19","underlying":"Common Stock","underlying_shares":2070},"source":{"system":"sec-edgar","filing":"0001415889-24-025436","document":"form4-10182024_101021.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":28,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924025436/form4-10182024_101021.xml","form_type":"4"}},{"id":1384166,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-10-18T22:51:26.000Z","date":"2024-10-16","kind":"exercise","planned":false,"acquired":false,"shares":2070,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"Immediately exercisable."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F6","text":"The securities are directly held by Mr. Lichter."}],"balance_after":9490,"derivative":{"exercise_price":10.73,"expiration_date":"2027-07-19","underlying":"Common Stock","underlying_shares":2070},"source":{"system":"sec-edgar","filing":"0001415889-24-025436","document":"form4-10182024_101021.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":27,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924025436/form4-10182024_101021.xml","form_type":"4"}},{"id":1384165,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-10-18T22:51:26.000Z","date":"2024-10-16","kind":"exercise","planned":false,"acquired":false,"shares":4968,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"Immediately exercisable."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F6","text":"The securities are directly held by Mr. Lichter."}],"balance_after":22776,"derivative":{"exercise_price":17,"expiration_date":"2027-07-19","underlying":"Common Stock","underlying_shares":4968},"source":{"system":"sec-edgar","filing":"0001415889-24-025436","document":"form4-10182024_101021.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":26,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924025436/form4-10182024_101021.xml","form_type":"4"}},{"id":1384164,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-18T22:51:26.000Z","date":"2024-10-18","kind":"sale","planned":false,"acquired":false,"shares":553219,"price":44.75,"value":24756550.25,"ownership":{"direct":false,"nature":"By Avalon BioVentures SPV I, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F11","text":"Shares sold in a private transaction pursuant to a stock purchase agreement dated September 12, 2024. The closing of the transaction was subject to certain customary conditions to closing, including the expiration or earlier termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. The closing conditions were satisfied, and the transaction closed, on October 18, 2024."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are directly held by Avalon BioVentures SPV I, LP (\"ABV SPV\"). ABV SPV I GP LLC (\"ABV SPV GP\") is the general partner of ABV SPV and may be deemed to beneficially own the securities held by ABV SPV. Mr. Lichter is a managing member of ABV SPV GP and shares voting and investment power with respect to the securities held by ABV SPV. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":2115373,"source":{"system":"sec-edgar","filing":"0001415889-24-025436","document":"form4-10182024_101021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":25,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924025436/form4-10182024_101021.xml","form_type":"4"}},{"id":1384163,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-18T22:51:26.000Z","date":"2024-10-18","kind":"sale","planned":false,"acquired":false,"shares":104957,"price":44.75,"value":4696825.75,"ownership":{"direct":false,"nature":"By Avalon BioVentures I, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F11","text":"Shares sold in a private transaction pursuant to a stock purchase agreement dated September 12, 2024. The closing of the transaction was subject to certain customary conditions to closing, including the expiration or earlier termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. The closing conditions were satisfied, and the transaction closed, on October 18, 2024."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by Avalon BioVentures I, LP (\"ABV I\"). Avalon BioVentures GP LLC (\"ABV GP\") is the general partner of ABV I and may be deemed to beneficially own the securities held by ABV I. Mr. Lichter is a managing member of ABV GP and shares voting and investment power with respect to the securities held by ABV I. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":401321,"source":{"system":"sec-edgar","filing":"0001415889-24-025436","document":"form4-10182024_101021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":24,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924025436/form4-10182024_101021.xml","form_type":"4"}},{"id":1384162,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-18T22:51:26.000Z","date":"2024-10-18","kind":"sale","planned":false,"acquired":false,"shares":541824,"price":44.75,"value":24246624.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F11","text":"Shares sold in a private transaction pursuant to a stock purchase agreement dated September 12, 2024. The closing of the transaction was subject to certain customary conditions to closing, including the expiration or earlier termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. The closing conditions were satisfied, and the transaction closed, on October 18, 2024."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities are directly held by Avalon Ventures XI, L.P. (\"Avalon Ventures\"). Avalon Ventures XI GP, LLC (\"Avalon XI GP\") is the general partner of Avalon Ventures and may be deemed to beneficially own the securities held by Avalon Ventures. Mr. Lichter is a managing member of Avalon XI GP and shares voting and investment power with respect to the securities held by Avalon Ventures. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":2071799,"source":{"system":"sec-edgar","filing":"0001415889-24-025436","document":"form4-10182024_101021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":23,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924025436/form4-10182024_101021.xml","form_type":"4"}},{"id":1384161,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-18T22:51:26.000Z","date":"2024-10-18","kind":"sale","planned":false,"acquired":false,"shares":15788,"price":51.18,"value":808029.84,"ownership":{"direct":false,"nature":"By Avalon BioVentures SPV I, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.00 to $51.97 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are directly held by Avalon BioVentures SPV I, LP (\"ABV SPV\"). ABV SPV I GP LLC (\"ABV SPV GP\") is the general partner of ABV SPV and may be deemed to beneficially own the securities held by ABV SPV. Mr. Lichter is a managing member of ABV SPV GP and shares voting and investment power with respect to the securities held by ABV SPV. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":2668592,"source":{"system":"sec-edgar","filing":"0001415889-24-025436","document":"form4-10182024_101021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":22,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924025436/form4-10182024_101021.xml","form_type":"4"}},{"id":1384160,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-18T22:51:26.000Z","date":"2024-10-18","kind":"sale","planned":false,"acquired":false,"shares":2995,"price":51.18,"value":153284.1,"ownership":{"direct":false,"nature":"By Avalon BioVentures I, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.00 to $51.97 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by Avalon BioVentures I, LP (\"ABV I\"). Avalon BioVentures GP LLC (\"ABV GP\") is the general partner of ABV I and may be deemed to beneficially own the securities held by ABV I. Mr. Lichter is a managing member of ABV GP and shares voting and investment power with respect to the securities held by ABV I. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":506278,"source":{"system":"sec-edgar","filing":"0001415889-24-025436","document":"form4-10182024_101021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924025436/form4-10182024_101021.xml","form_type":"4"}},{"id":1384159,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-18T22:51:26.000Z","date":"2024-10-18","kind":"sale","planned":false,"acquired":false,"shares":15462,"price":51.18,"value":791345.16,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.00 to $51.97 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities are directly held by Avalon Ventures XI, L.P. (\"Avalon Ventures\"). Avalon Ventures XI GP, LLC (\"Avalon XI GP\") is the general partner of Avalon Ventures and may be deemed to beneficially own the securities held by Avalon Ventures. Mr. Lichter is a managing member of Avalon XI GP and shares voting and investment power with respect to the securities held by Avalon Ventures. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":2613623,"source":{"system":"sec-edgar","filing":"0001415889-24-025436","document":"form4-10182024_101021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924025436/form4-10182024_101021.xml","form_type":"4"}},{"id":1384158,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-18T22:51:26.000Z","date":"2024-10-18","kind":"sale","planned":false,"acquired":false,"shares":104892,"price":50.3,"value":5276067.6,"ownership":{"direct":false,"nature":"By Avalon BioVentures SPV I, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.86 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are directly held by Avalon BioVentures SPV I, LP (\"ABV SPV\"). ABV SPV I GP LLC (\"ABV SPV GP\") is the general partner of ABV SPV and may be deemed to beneficially own the securities held by ABV SPV. Mr. Lichter is a managing member of ABV SPV GP and shares voting and investment power with respect to the securities held by ABV SPV. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":2684380,"source":{"system":"sec-edgar","filing":"0001415889-24-025436","document":"form4-10182024_101021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924025436/form4-10182024_101021.xml","form_type":"4"}},{"id":1384157,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-18T22:51:26.000Z","date":"2024-10-18","kind":"sale","planned":false,"acquired":false,"shares":19900,"price":50.3,"value":1000970.0,"ownership":{"direct":false,"nature":"By Avalon BioVentures I, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.86 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by Avalon BioVentures I, LP (\"ABV I\"). Avalon BioVentures GP LLC (\"ABV GP\") is the general partner of ABV I and may be deemed to beneficially own the securities held by ABV I. Mr. Lichter is a managing member of ABV GP and shares voting and investment power with respect to the securities held by ABV I. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":509273,"source":{"system":"sec-edgar","filing":"0001415889-24-025436","document":"form4-10182024_101021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924025436/form4-10182024_101021.xml","form_type":"4"}},{"id":1384156,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-18T22:51:26.000Z","date":"2024-10-18","kind":"sale","planned":false,"acquired":false,"shares":102732,"price":50.3,"value":5167419.6,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.86 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities are directly held by Avalon Ventures XI, L.P. (\"Avalon Ventures\"). Avalon Ventures XI GP, LLC (\"Avalon XI GP\") is the general partner of Avalon Ventures and may be deemed to beneficially own the securities held by Avalon Ventures. Mr. Lichter is a managing member of Avalon XI GP and shares voting and investment power with respect to the securities held by Avalon Ventures. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":2629085,"source":{"system":"sec-edgar","filing":"0001415889-24-025436","document":"form4-10182024_101021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924025436/form4-10182024_101021.xml","form_type":"4"}},{"id":1384155,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-18T22:51:26.000Z","date":"2024-10-17","kind":"sale","planned":false,"acquired":false,"shares":1843,"price":50.02,"value":92186.86,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.97 to $50.18 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F6","text":"The securities are directly held by Mr. Lichter."}],"balance_after":6371,"source":{"system":"sec-edgar","filing":"0001415889-24-025436","document":"form4-10182024_101021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924025436/form4-10182024_101021.xml","form_type":"4"}},{"id":1384154,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-18T22:51:26.000Z","date":"2024-10-17","kind":"exercise","planned":false,"acquired":true,"shares":237,"price":39.8,"value":9432.6,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F6","text":"The securities are directly held by Mr. Lichter."}],"balance_after":8214,"source":{"system":"sec-edgar","filing":"0001415889-24-025436","document":"form4-10182024_101021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924025436/form4-10182024_101021.xml","form_type":"4"}},{"id":1384153,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-18T22:51:26.000Z","date":"2024-10-17","kind":"exercise","planned":false,"acquired":true,"shares":348,"price":13.22,"value":4600.56,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F6","text":"The securities are directly held by Mr. Lichter."}],"balance_after":7977,"source":{"system":"sec-edgar","filing":"0001415889-24-025436","document":"form4-10182024_101021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924025436/form4-10182024_101021.xml","form_type":"4"}},{"id":1384152,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-18T22:51:26.000Z","date":"2024-10-17","kind":"exercise","planned":false,"acquired":true,"shares":348,"price":10.73,"value":3734.04,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F6","text":"The securities are directly held by Mr. Lichter."}],"balance_after":7629,"source":{"system":"sec-edgar","filing":"0001415889-24-025436","document":"form4-10182024_101021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924025436/form4-10182024_101021.xml","form_type":"4"}},{"id":1384151,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-18T22:51:26.000Z","date":"2024-10-17","kind":"exercise","planned":false,"acquired":true,"shares":836,"price":17,"value":14212.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F6","text":"The securities are directly held by Mr. Lichter."}],"balance_after":7281,"source":{"system":"sec-edgar","filing":"0001415889-24-025436","document":"form4-10182024_101021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924025436/form4-10182024_101021.xml","form_type":"4"}},{"id":1384150,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-18T22:51:26.000Z","date":"2024-10-16","kind":"sale","planned":false,"acquired":false,"shares":10957,"price":50.8,"value":556615.6,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.76 to $51.05 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F6","text":"The securities are directly held by Mr. Lichter."}],"balance_after":6445,"source":{"system":"sec-edgar","filing":"0001415889-24-025436","document":"form4-10182024_101021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924025436/form4-10182024_101021.xml","form_type":"4"}},{"id":1384149,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-18T22:51:26.000Z","date":"2024-10-16","kind":"exercise","planned":false,"acquired":true,"shares":1407,"price":39.8,"value":55998.6,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F6","text":"The securities are directly held by Mr. Lichter."}],"balance_after":17402,"source":{"system":"sec-edgar","filing":"0001415889-24-025436","document":"form4-10182024_101021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924025436/form4-10182024_101021.xml","form_type":"4"}},{"id":1384148,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-18T22:51:26.000Z","date":"2024-10-16","kind":"exercise","planned":false,"acquired":true,"shares":2070,"price":13.22,"value":27365.4,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F6","text":"The securities are directly held by Mr. Lichter."}],"balance_after":15995,"source":{"system":"sec-edgar","filing":"0001415889-24-025436","document":"form4-10182024_101021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924025436/form4-10182024_101021.xml","form_type":"4"}},{"id":1384147,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-18T22:51:26.000Z","date":"2024-10-16","kind":"exercise","planned":false,"acquired":true,"shares":2070,"price":10.73,"value":22211.1,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F6","text":"The securities are directly held by Mr. Lichter."}],"balance_after":13925,"source":{"system":"sec-edgar","filing":"0001415889-24-025436","document":"form4-10182024_101021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924025436/form4-10182024_101021.xml","form_type":"4"}},{"id":1384146,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-18T22:51:26.000Z","date":"2024-10-16","kind":"exercise","planned":false,"acquired":true,"shares":4968,"price":17,"value":84456.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F6","text":"The securities are directly held by Mr. Lichter."}],"balance_after":11855,"source":{"system":"sec-edgar","filing":"0001415889-24-025436","document":"form4-10182024_101021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924025436/form4-10182024_101021.xml","form_type":"4"}},{"id":1384145,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-18T22:51:26.000Z","date":"2024-10-16","kind":"sale","planned":false,"acquired":false,"shares":30094,"price":50.61,"value":1523057.34,"ownership":{"direct":false,"nature":"By Avalon BioVentures SPV I, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $50.46 to $51.25 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are directly held by Avalon BioVentures SPV I, LP (\"ABV SPV\"). ABV SPV I GP LLC (\"ABV SPV GP\") is the general partner of ABV SPV and may be deemed to beneficially own the securities held by ABV SPV. Mr. Lichter is a managing member of ABV SPV GP and shares voting and investment power with respect to the securities held by ABV SPV. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":2789272,"source":{"system":"sec-edgar","filing":"0001415889-24-025436","document":"form4-10182024_101021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924025436/form4-10182024_101021.xml","form_type":"4"}},{"id":1384144,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-18T22:51:26.000Z","date":"2024-10-16","kind":"sale","planned":false,"acquired":false,"shares":5710,"price":50.61,"value":288983.1,"ownership":{"direct":false,"nature":"By Avalon BioVentures I, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $50.46 to $51.25 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by Avalon BioVentures I, LP (\"ABV I\"). Avalon BioVentures GP LLC (\"ABV GP\") is the general partner of ABV I and may be deemed to beneficially own the securities held by ABV I. Mr. Lichter is a managing member of ABV GP and shares voting and investment power with respect to the securities held by ABV I. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":529173,"source":{"system":"sec-edgar","filing":"0001415889-24-025436","document":"form4-10182024_101021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924025436/form4-10182024_101021.xml","form_type":"4"}},{"id":1384143,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-18T22:51:26.000Z","date":"2024-10-16","kind":"sale","planned":false,"acquired":false,"shares":29474,"price":50.61,"value":1491679.14,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $50.46 to $51.25 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities are directly held by Avalon Ventures XI, L.P. (\"Avalon Ventures\"). Avalon Ventures XI GP, LLC (\"Avalon XI GP\") is the general partner of Avalon Ventures and may be deemed to beneficially own the securities held by Avalon Ventures. Mr. Lichter is a managing member of Avalon XI GP and shares voting and investment power with respect to the securities held by Avalon Ventures. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":2731817,"source":{"system":"sec-edgar","filing":"0001415889-24-025436","document":"form4-10182024_101021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924025436/form4-10182024_101021.xml","form_type":"4"}},{"id":1384142,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-18T22:51:26.000Z","date":"2024-10-16","kind":"sale","planned":false,"acquired":false,"shares":61445,"price":49.69,"value":3053202.05,"ownership":{"direct":false,"nature":"By Avalon BioVentures SPV I, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $49.50 to $50.45 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are directly held by Avalon BioVentures SPV I, LP (\"ABV SPV\"). ABV SPV I GP LLC (\"ABV SPV GP\") is the general partner of ABV SPV and may be deemed to beneficially own the securities held by ABV SPV. Mr. Lichter is a managing member of ABV SPV GP and shares voting and investment power with respect to the securities held by ABV SPV. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":2819366,"source":{"system":"sec-edgar","filing":"0001415889-24-025436","document":"form4-10182024_101021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924025436/form4-10182024_101021.xml","form_type":"4"}},{"id":1384141,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-18T22:51:26.000Z","date":"2024-10-16","kind":"sale","planned":false,"acquired":false,"shares":11657,"price":49.69,"value":579236.33,"ownership":{"direct":false,"nature":"By Avalon BioVentures I, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $49.50 to $50.45 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by Avalon BioVentures I, LP (\"ABV I\"). Avalon BioVentures GP LLC (\"ABV GP\") is the general partner of ABV I and may be deemed to beneficially own the securities held by ABV I. Mr. Lichter is a managing member of ABV GP and shares voting and investment power with respect to the securities held by ABV I. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":534883,"source":{"system":"sec-edgar","filing":"0001415889-24-025436","document":"form4-10182024_101021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924025436/form4-10182024_101021.xml","form_type":"4"}},{"id":1384140,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-18T22:51:26.000Z","date":"2024-10-16","kind":"sale","planned":false,"acquired":false,"shares":60179,"price":49.69,"value":2990294.51,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $49.50 to $50.45 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities are directly held by Avalon Ventures XI, L.P. (\"Avalon Ventures\"). Avalon Ventures XI GP, LLC (\"Avalon XI GP\") is the general partner of Avalon Ventures and may be deemed to beneficially own the securities held by Avalon Ventures. Mr. Lichter is a managing member of Avalon XI GP and shares voting and investment power with respect to the securities held by Avalon Ventures. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":2761291,"source":{"system":"sec-edgar","filing":"0001415889-24-025436","document":"form4-10182024_101021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924025436/form4-10182024_101021.xml","form_type":"4"}},{"id":1397946,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-10-01T00:49:38.000Z","date":"2024-09-30","kind":"exercise","planned":false,"acquired":false,"shares":123,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"Immediately exercisable."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F8","text":"The securities are directly held by Mr. Lichter."}],"balance_after":7716,"derivative":{"exercise_price":39.8,"expiration_date":"2027-07-19","underlying":"Common Stock","underlying_shares":123},"source":{"system":"sec-edgar","filing":"0001415889-24-024119","document":"form4-10012024_121033.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":30,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924024119/form4-10012024_121033.xml","form_type":"4"}},{"id":1397945,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-10-01T00:49:38.000Z","date":"2024-09-30","kind":"exercise","planned":false,"acquired":false,"shares":181,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"Immediately exercisable."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F8","text":"The securities are directly held by Mr. Lichter."}],"balance_after":11560,"derivative":{"exercise_price":13.22,"expiration_date":"2027-07-19","underlying":"Common Stock","underlying_shares":181},"source":{"system":"sec-edgar","filing":"0001415889-24-024119","document":"form4-10012024_121033.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":29,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924024119/form4-10012024_121033.xml","form_type":"4"}},{"id":1397944,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-10-01T00:49:38.000Z","date":"2024-09-30","kind":"exercise","planned":false,"acquired":false,"shares":181,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"Immediately exercisable."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F8","text":"The securities are directly held by Mr. Lichter."}],"balance_after":11560,"derivative":{"exercise_price":10.73,"expiration_date":"2027-07-19","underlying":"Common Stock","underlying_shares":181},"source":{"system":"sec-edgar","filing":"0001415889-24-024119","document":"form4-10012024_121033.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":28,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924024119/form4-10012024_121033.xml","form_type":"4"}},{"id":1397943,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-10-01T00:49:38.000Z","date":"2024-09-30","kind":"exercise","planned":false,"acquired":false,"shares":434,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"Immediately exercisable."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F8","text":"The securities are directly held by Mr. Lichter."}],"balance_after":27744,"derivative":{"exercise_price":17,"expiration_date":"2027-07-19","underlying":"Common Stock","underlying_shares":434},"source":{"system":"sec-edgar","filing":"0001415889-24-024119","document":"form4-10012024_121033.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":27,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924024119/form4-10012024_121033.xml","form_type":"4"}},{"id":1397942,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-10-01T00:49:38.000Z","date":"2024-09-27","kind":"exercise","planned":false,"acquired":false,"shares":234,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"Immediately exercisable."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F8","text":"The securities are directly held by Mr. Lichter."}],"balance_after":7839,"derivative":{"exercise_price":39.8,"expiration_date":"2027-07-19","underlying":"Common Stock","underlying_shares":234},"source":{"system":"sec-edgar","filing":"0001415889-24-024119","document":"form4-10012024_121033.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":26,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924024119/form4-10012024_121033.xml","form_type":"4"}},{"id":1397941,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-10-01T00:49:38.000Z","date":"2024-09-27","kind":"exercise","planned":false,"acquired":false,"shares":345,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"Immediately exercisable."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F8","text":"The securities are directly held by Mr. Lichter."}],"balance_after":11741,"derivative":{"exercise_price":13.22,"expiration_date":"2027-07-19","underlying":"Common Stock","underlying_shares":345},"source":{"system":"sec-edgar","filing":"0001415889-24-024119","document":"form4-10012024_121033.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":25,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924024119/form4-10012024_121033.xml","form_type":"4"}},{"id":1397940,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-10-01T00:49:38.000Z","date":"2024-09-27","kind":"exercise","planned":false,"acquired":false,"shares":345,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"Immediately exercisable."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F8","text":"The securities are directly held by Mr. Lichter."}],"balance_after":11741,"derivative":{"exercise_price":10.73,"expiration_date":"2027-07-19","underlying":"Common Stock","underlying_shares":345},"source":{"system":"sec-edgar","filing":"0001415889-24-024119","document":"form4-10012024_121033.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":24,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924024119/form4-10012024_121033.xml","form_type":"4"}},{"id":1397939,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-10-01T00:49:38.000Z","date":"2024-09-27","kind":"exercise","planned":false,"acquired":false,"shares":828,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"Immediately exercisable."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F8","text":"The securities are directly held by Mr. Lichter."}],"balance_after":28178,"derivative":{"exercise_price":17,"expiration_date":"2027-07-19","underlying":"Common Stock","underlying_shares":828},"source":{"system":"sec-edgar","filing":"0001415889-24-024119","document":"form4-10012024_121033.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":23,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924024119/form4-10012024_121033.xml","form_type":"4"}},{"id":1397938,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-01T00:49:38.000Z","date":"2024-09-30","kind":"sale","planned":false,"acquired":false,"shares":958,"price":46.24,"value":44297.92,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.24 to $46.31 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F8","text":"The securities are directly held by Mr. Lichter."}],"balance_after":6887,"source":{"system":"sec-edgar","filing":"0001415889-24-024119","document":"form4-10012024_121033.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":22,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924024119/form4-10012024_121033.xml","form_type":"4"}},{"id":1397937,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-01T00:49:38.000Z","date":"2024-09-30","kind":"exercise","planned":false,"acquired":true,"shares":123,"price":39.8,"value":4895.4,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F8","text":"The securities are directly held by Mr. Lichter."}],"balance_after":7845,"source":{"system":"sec-edgar","filing":"0001415889-24-024119","document":"form4-10012024_121033.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924024119/form4-10012024_121033.xml","form_type":"4"}},{"id":1397936,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-01T00:49:38.000Z","date":"2024-09-30","kind":"exercise","planned":false,"acquired":true,"shares":181,"price":13.22,"value":2392.82,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F8","text":"The securities are directly held by Mr. Lichter."}],"balance_after":7722,"source":{"system":"sec-edgar","filing":"0001415889-24-024119","document":"form4-10012024_121033.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924024119/form4-10012024_121033.xml","form_type":"4"}},{"id":1397935,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-01T00:49:38.000Z","date":"2024-09-30","kind":"exercise","planned":false,"acquired":true,"shares":181,"price":10.73,"value":1942.13,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F8","text":"The securities are directly held by Mr. Lichter."}],"balance_after":7541,"source":{"system":"sec-edgar","filing":"0001415889-24-024119","document":"form4-10012024_121033.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924024119/form4-10012024_121033.xml","form_type":"4"}},{"id":1397934,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-01T00:49:38.000Z","date":"2024-09-30","kind":"exercise","planned":false,"acquired":true,"shares":434,"price":17,"value":7378.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F8","text":"The securities are directly held by Mr. Lichter."}],"balance_after":7360,"source":{"system":"sec-edgar","filing":"0001415889-24-024119","document":"form4-10012024_121033.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924024119/form4-10012024_121033.xml","form_type":"4"}},{"id":1397933,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-01T00:49:38.000Z","date":"2024-09-27","kind":"sale","planned":false,"acquired":false,"shares":1826,"price":46.19,"value":84342.94,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.11 to $46.22 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F8","text":"The securities are directly held by Mr. Lichter."}],"balance_after":6926,"source":{"system":"sec-edgar","filing":"0001415889-24-024119","document":"form4-10012024_121033.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924024119/form4-10012024_121033.xml","form_type":"4"}},{"id":1397932,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-01T00:49:38.000Z","date":"2024-09-27","kind":"exercise","planned":false,"acquired":true,"shares":234,"price":39.8,"value":9313.2,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F8","text":"The securities are directly held by Mr. Lichter."}],"balance_after":8752,"source":{"system":"sec-edgar","filing":"0001415889-24-024119","document":"form4-10012024_121033.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924024119/form4-10012024_121033.xml","form_type":"4"}},{"id":1397931,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-01T00:49:38.000Z","date":"2024-09-27","kind":"exercise","planned":false,"acquired":true,"shares":345,"price":13.22,"value":4560.9,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F8","text":"The securities are directly held by Mr. Lichter."}],"balance_after":8518,"source":{"system":"sec-edgar","filing":"0001415889-24-024119","document":"form4-10012024_121033.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924024119/form4-10012024_121033.xml","form_type":"4"}},{"id":1397930,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-01T00:49:38.000Z","date":"2024-09-27","kind":"exercise","planned":false,"acquired":true,"shares":345,"price":10.73,"value":3701.85,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F8","text":"The securities are directly held by Mr. Lichter."}],"balance_after":8173,"source":{"system":"sec-edgar","filing":"0001415889-24-024119","document":"form4-10012024_121033.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924024119/form4-10012024_121033.xml","form_type":"4"}},{"id":1397929,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-01T00:49:38.000Z","date":"2024-09-27","kind":"exercise","planned":false,"acquired":true,"shares":828,"price":17,"value":14076.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F8","text":"The securities are directly held by Mr. Lichter."}],"balance_after":7828,"source":{"system":"sec-edgar","filing":"0001415889-24-024119","document":"form4-10012024_121033.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924024119/form4-10012024_121033.xml","form_type":"4"}},{"id":1397928,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-01T00:49:38.000Z","date":"2024-09-27","kind":"sale","planned":false,"acquired":false,"shares":1542,"price":47.74,"value":73615.08,"ownership":{"direct":false,"nature":"By Avalon BioVentures SPV I, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.28 to $47.97 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are directly held by Avalon BioVentures SPV I, LP (\"ABV SPV\"). ABV SPV I GP LLC (\"ABV SPV GP\") is the general partner of ABV SPV and may be deemed to beneficially own the securities held by ABV SPV. Mr. Lichter is a managing member of ABV SPV GP and shares voting and investment power with respect to the securities held by ABV SPV. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":2880811,"source":{"system":"sec-edgar","filing":"0001415889-24-024119","document":"form4-10012024_121033.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924024119/form4-10012024_121033.xml","form_type":"4"}},{"id":1397927,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-01T00:49:38.000Z","date":"2024-09-27","kind":"sale","planned":false,"acquired":false,"shares":293,"price":47.74,"value":13987.82,"ownership":{"direct":false,"nature":"By Avalon BioVentures I, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.28 to $47.97 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by Avalon BioVentures I, LP (\"ABV I\"). Avalon BioVentures GP LLC (\"ABV GP\") is the general partner of ABV I and may be deemed to beneficially own the securities held by ABV I. Mr. Lichter is a managing member of ABV GP and shares voting and investment power with respect to the securities held by ABV I. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":546540,"source":{"system":"sec-edgar","filing":"0001415889-24-024119","document":"form4-10012024_121033.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924024119/form4-10012024_121033.xml","form_type":"4"}},{"id":1397926,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-01T00:49:38.000Z","date":"2024-09-27","kind":"sale","planned":false,"acquired":false,"shares":1511,"price":47.74,"value":72135.14,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.28 to $47.97 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities are directly held by Avalon Ventures XI, L.P. (\"Avalon Ventures\"). Avalon Ventures XI GP, LLC (\"Avalon XI GP\") is the general partner of Avalon Ventures and may be deemed to beneficially own the securities held by Avalon Ventures. Mr. Lichter is a managing member of Avalon XI GP and shares voting and investment power with respect to the securities held by Avalon Ventures. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":2821470,"source":{"system":"sec-edgar","filing":"0001415889-24-024119","document":"form4-10012024_121033.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924024119/form4-10012024_121033.xml","form_type":"4"}},{"id":1397925,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-01T00:49:38.000Z","date":"2024-09-27","kind":"sale","planned":false,"acquired":false,"shares":46861,"price":46.42,"value":2175287.62,"ownership":{"direct":false,"nature":"By Avalon BioVentures SPV I, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.25 to $47.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are directly held by Avalon BioVentures SPV I, LP (\"ABV SPV\"). ABV SPV I GP LLC (\"ABV SPV GP\") is the general partner of ABV SPV and may be deemed to beneficially own the securities held by ABV SPV. Mr. Lichter is a managing member of ABV SPV GP and shares voting and investment power with respect to the securities held by ABV SPV. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":2882353,"source":{"system":"sec-edgar","filing":"0001415889-24-024119","document":"form4-10012024_121033.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924024119/form4-10012024_121033.xml","form_type":"4"}},{"id":1397924,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-01T00:49:38.000Z","date":"2024-09-27","kind":"sale","planned":false,"acquired":false,"shares":8894,"price":46.42,"value":412859.48,"ownership":{"direct":false,"nature":"By Avalon BioVentures I, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.25 to $47.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by Avalon BioVentures I, LP (\"ABV I\"). Avalon BioVentures GP LLC (\"ABV GP\") is the general partner of ABV I and may be deemed to beneficially own the securities held by ABV I. Mr. Lichter is a managing member of ABV GP and shares voting and investment power with respect to the securities held by ABV I. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":546833,"source":{"system":"sec-edgar","filing":"0001415889-24-024119","document":"form4-10012024_121033.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924024119/form4-10012024_121033.xml","form_type":"4"}},{"id":1397923,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-01T00:49:38.000Z","date":"2024-09-27","kind":"sale","planned":false,"acquired":false,"shares":45894,"price":46.42,"value":2130399.48,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.25 to $47.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities are directly held by Avalon Ventures XI, L.P. (\"Avalon Ventures\"). Avalon Ventures XI GP, LLC (\"Avalon XI GP\") is the general partner of Avalon Ventures and may be deemed to beneficially own the securities held by Avalon Ventures. Mr. Lichter is a managing member of Avalon XI GP and shares voting and investment power with respect to the securities held by Avalon Ventures. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":2822981,"source":{"system":"sec-edgar","filing":"0001415889-24-024119","document":"form4-10012024_121033.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924024119/form4-10012024_121033.xml","form_type":"4"}},{"id":1397922,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-01T00:49:38.000Z","date":"2024-09-26","kind":"sale","planned":false,"acquired":false,"shares":41661,"price":47.77,"value":1990145.97,"ownership":{"direct":false,"nature":"By Avalon BioVentures SPV I, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $47.50 to $48.14 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are directly held by Avalon BioVentures SPV I, LP (\"ABV SPV\"). ABV SPV I GP LLC (\"ABV SPV GP\") is the general partner of ABV SPV and may be deemed to beneficially own the securities held by ABV SPV. Mr. Lichter is a managing member of ABV SPV GP and shares voting and investment power with respect to the securities held by ABV SPV. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":2929214,"source":{"system":"sec-edgar","filing":"0001415889-24-024119","document":"form4-10012024_121033.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924024119/form4-10012024_121033.xml","form_type":"4"}},{"id":1397921,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-01T00:49:38.000Z","date":"2024-09-26","kind":"sale","planned":false,"acquired":false,"shares":7908,"price":47.77,"value":377765.16,"ownership":{"direct":false,"nature":"By Avalon BioVentures I, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $47.50 to $48.14 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by Avalon BioVentures I, LP (\"ABV I\"). Avalon BioVentures GP LLC (\"ABV GP\") is the general partner of ABV I and may be deemed to beneficially own the securities held by ABV I. Mr. Lichter is a managing member of ABV GP and shares voting and investment power with respect to the securities held by ABV I. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":555727,"source":{"system":"sec-edgar","filing":"0001415889-24-024119","document":"form4-10012024_121033.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924024119/form4-10012024_121033.xml","form_type":"4"}},{"id":1397920,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-01T00:49:38.000Z","date":"2024-09-26","kind":"sale","planned":false,"acquired":false,"shares":40803,"price":47.77,"value":1949159.31,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $47.50 to $48.14 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities are directly held by Avalon Ventures XI, L.P. (\"Avalon Ventures\"). Avalon Ventures XI GP, LLC (\"Avalon XI GP\") is the general partner of Avalon Ventures and may be deemed to beneficially own the securities held by Avalon Ventures. Mr. Lichter is a managing member of Avalon XI GP and shares voting and investment power with respect to the securities held by Avalon Ventures. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":2868875,"source":{"system":"sec-edgar","filing":"0001415889-24-024119","document":"form4-10012024_121033.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924024119/form4-10012024_121033.xml","form_type":"4"}},{"id":1397919,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-01T00:49:38.000Z","date":"2024-09-26","kind":"sale","planned":false,"acquired":false,"shares":50539,"price":46.78,"value":2364214.42,"ownership":{"direct":false,"nature":"By Avalon BioVentures SPV I, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $46.50 to $47.49 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are directly held by Avalon BioVentures SPV I, LP (\"ABV SPV\"). ABV SPV I GP LLC (\"ABV SPV GP\") is the general partner of ABV SPV and may be deemed to beneficially own the securities held by ABV SPV. Mr. Lichter is a managing member of ABV SPV GP and shares voting and investment power with respect to the securities held by ABV SPV. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":2970875,"source":{"system":"sec-edgar","filing":"0001415889-24-024119","document":"form4-10012024_121033.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924024119/form4-10012024_121033.xml","form_type":"4"}},{"id":1397918,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-01T00:49:38.000Z","date":"2024-09-26","kind":"sale","planned":false,"acquired":false,"shares":9592,"price":46.78,"value":448713.76,"ownership":{"direct":false,"nature":"By Avalon BioVentures I, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $46.50 to $47.49 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by Avalon BioVentures I, LP (\"ABV I\"). Avalon BioVentures GP LLC (\"ABV GP\") is the general partner of ABV I and may be deemed to beneficially own the securities held by ABV I. Mr. Lichter is a managing member of ABV GP and shares voting and investment power with respect to the securities held by ABV I. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":563635,"source":{"system":"sec-edgar","filing":"0001415889-24-024119","document":"form4-10012024_121033.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924024119/form4-10012024_121033.xml","form_type":"4"}},{"id":1397917,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-01T00:49:38.000Z","date":"2024-09-26","kind":"sale","planned":false,"acquired":false,"shares":49497,"price":46.78,"value":2315469.66,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $46.50 to $47.49 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities are directly held by Avalon Ventures XI, L.P. (\"Avalon Ventures\"). Avalon Ventures XI GP, LLC (\"Avalon XI GP\") is the general partner of Avalon Ventures and may be deemed to beneficially own the securities held by Avalon Ventures. Mr. Lichter is a managing member of Avalon XI GP and shares voting and investment power with respect to the securities held by Avalon Ventures. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":2909678,"source":{"system":"sec-edgar","filing":"0001415889-24-024119","document":"form4-10012024_121033.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924024119/form4-10012024_121033.xml","form_type":"4"}},{"id":1408742,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-09-13T00:42:19.000Z","date":"2024-09-12","kind":"sale","planned":false,"acquired":false,"shares":161356,"price":47,"value":7583732.0,"ownership":{"direct":false,"nature":"By Avalon BioVentures SPV I, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are directly held by Avalon BioVentures SPV I, LP (\"ABV SPV\"). ABV SPV I GP LLC (\"ABV SPV GP\") is the general partner of ABV SPV and may be deemed to beneficially own the securities held by ABV SPV. Mr. Lichter is a managing member of ABV SPV GP and shares voting and investment power with respect to the securities held by ABV SPV. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":3021414,"source":{"system":"sec-edgar","filing":"0001415889-24-023337","document":"form4-09132024_120915.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924023337/form4-09132024_120915.xml","form_type":"4"}},{"id":1408741,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-09-13T00:42:19.000Z","date":"2024-09-12","kind":"sale","planned":false,"acquired":false,"shares":30613,"price":47,"value":1438811.0,"ownership":{"direct":false,"nature":"By Avalon BioVentures I, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by Avalon BioVentures I, LP (\"ABV I\"). Avalon BioVentures GP LLC (\"ABV GP\") is the general partner of ABV I and may be deemed to beneficially own the securities held by ABV I. Mr. Lichter is a managing member of ABV GP and shares voting and investment power with respect to the securities held by ABV I. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":573227,"source":{"system":"sec-edgar","filing":"0001415889-24-023337","document":"form4-09132024_120915.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924023337/form4-09132024_120915.xml","form_type":"4"}},{"id":1408740,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-09-13T00:42:19.000Z","date":"2024-09-12","kind":"sale","planned":false,"acquired":false,"shares":158031,"price":47,"value":7427457.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities are directly held by Avalon Ventures XI, L.P. (\"Avalon Ventures\"). Avalon Ventures XI GP, LLC (\"Avalon XI GP\") is the general partner of Avalon Ventures and may be deemed to beneficially own the securities held by Avalon Ventures. Mr. Lichter is a managing member of Avalon XI GP and shares voting and investment power with respect to the securities held by Avalon Ventures. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":2959175,"source":{"system":"sec-edgar","filing":"0001415889-24-023337","document":"form4-09132024_120915.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924023337/form4-09132024_120915.xml","form_type":"4"}},{"id":1408739,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-09-13T00:42:19.000Z","date":"2024-09-10","kind":"sale","planned":false,"acquired":false,"shares":35047,"price":46.66,"value":1635293.02,"ownership":{"direct":false,"nature":"By Avalon BioVentures SPV I, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $46.50 to $47.02 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are directly held by Avalon BioVentures SPV I, LP (\"ABV SPV\"). ABV SPV I GP LLC (\"ABV SPV GP\") is the general partner of ABV SPV and may be deemed to beneficially own the securities held by ABV SPV. Mr. Lichter is a managing member of ABV SPV GP and shares voting and investment power with respect to the securities held by ABV SPV. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":3182770,"source":{"system":"sec-edgar","filing":"0001415889-24-023337","document":"form4-09132024_120915.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924023337/form4-09132024_120915.xml","form_type":"4"}},{"id":1408738,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-09-13T00:42:19.000Z","date":"2024-09-10","kind":"sale","planned":false,"acquired":false,"shares":6649,"price":46.66,"value":310242.34,"ownership":{"direct":false,"nature":"By Avalon BioVentures I, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $46.50 to $47.02 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by Avalon BioVentures I, LP (\"ABV I\"). Avalon BioVentures GP LLC (\"ABV GP\") is the general partner of ABV I and may be deemed to beneficially own the securities held by ABV I. Mr. Lichter is a managing member of ABV GP and shares voting and investment power with respect to the securities held by ABV I. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":603840,"source":{"system":"sec-edgar","filing":"0001415889-24-023337","document":"form4-09132024_120915.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924023337/form4-09132024_120915.xml","form_type":"4"}},{"id":1408737,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-09-13T00:42:19.000Z","date":"2024-09-10","kind":"sale","planned":false,"acquired":false,"shares":34326,"price":46.66,"value":1601651.16,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $46.50 to $47.02 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities are directly held by Avalon Ventures XI, L.P. (\"Avalon Ventures\"). Avalon Ventures XI GP, LLC (\"Avalon XI GP\") is the general partner of Avalon Ventures and may be deemed to beneficially own the securities held by Avalon Ventures. Mr. Lichter is a managing member of Avalon XI GP and shares voting and investment power with respect to the securities held by Avalon Ventures. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":3117206,"source":{"system":"sec-edgar","filing":"0001415889-24-023337","document":"form4-09132024_120915.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924023337/form4-09132024_120915.xml","form_type":"4"}},{"id":1408736,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-09-13T00:42:19.000Z","date":"2024-09-10","kind":"sale","planned":false,"acquired":false,"shares":11557,"price":46.13,"value":533124.41,"ownership":{"direct":false,"nature":"By Avalon BioVentures SPV I, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $45.50 to $46.47 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are directly held by Avalon BioVentures SPV I, LP (\"ABV SPV\"). ABV SPV I GP LLC (\"ABV SPV GP\") is the general partner of ABV SPV and may be deemed to beneficially own the securities held by ABV SPV. Mr. Lichter is a managing member of ABV SPV GP and shares voting and investment power with respect to the securities held by ABV SPV. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":3217817,"source":{"system":"sec-edgar","filing":"0001415889-24-023337","document":"form4-09132024_120915.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924023337/form4-09132024_120915.xml","form_type":"4"}},{"id":1408735,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-09-13T00:42:19.000Z","date":"2024-09-10","kind":"sale","planned":false,"acquired":false,"shares":2193,"price":46.13,"value":101163.09,"ownership":{"direct":false,"nature":"By Avalon BioVentures I, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $45.50 to $46.47 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by Avalon BioVentures I, LP (\"ABV I\"). Avalon BioVentures GP LLC (\"ABV GP\") is the general partner of ABV I and may be deemed to beneficially own the securities held by ABV I. Mr. Lichter is a managing member of ABV GP and shares voting and investment power with respect to the securities held by ABV I. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":610489,"source":{"system":"sec-edgar","filing":"0001415889-24-023337","document":"form4-09132024_120915.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924023337/form4-09132024_120915.xml","form_type":"4"}},{"id":1408734,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-09-13T00:42:19.000Z","date":"2024-09-10","kind":"sale","planned":false,"acquired":false,"shares":11319,"price":46.13,"value":522145.47,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $45.50 to $46.47 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities are directly held by Avalon Ventures XI, L.P. (\"Avalon Ventures\"). Avalon Ventures XI GP, LLC (\"Avalon XI GP\") is the general partner of Avalon Ventures and may be deemed to beneficially own the securities held by Avalon Ventures. Mr. Lichter is a managing member of Avalon XI GP and shares voting and investment power with respect to the securities held by Avalon Ventures. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":3151532,"source":{"system":"sec-edgar","filing":"0001415889-24-023337","document":"form4-09132024_120915.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924023337/form4-09132024_120915.xml","form_type":"4"}},{"id":1410919,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-09-10T21:02:56.000Z","date":"2024-09-09","kind":"exercise","planned":false,"acquired":false,"shares":277,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Immediately exercisable."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"The securities are directly held by Mr. Lichter."}],"balance_after":8073,"derivative":{"exercise_price":39.8,"expiration_date":"2027-07-19","underlying":"Common Stock","underlying_shares":277},"source":{"system":"sec-edgar","filing":"0001415889-24-023153","document":"form4-09102024_090952.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924023153/form4-09102024_090952.xml","form_type":"4"}},{"id":1410918,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-09-10T21:02:56.000Z","date":"2024-09-09","kind":"exercise","planned":false,"acquired":false,"shares":414,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Immediately exercisable."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"The securities are directly held by Mr. Lichter."}],"balance_after":12086,"derivative":{"exercise_price":13.22,"expiration_date":"2027-07-19","underlying":"Common Stock","underlying_shares":414},"source":{"system":"sec-edgar","filing":"0001415889-24-023153","document":"form4-09102024_090952.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924023153/form4-09102024_090952.xml","form_type":"4"}},{"id":1410917,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-09-10T21:02:56.000Z","date":"2024-09-09","kind":"exercise","planned":false,"acquired":false,"shares":414,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Immediately exercisable."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"The securities are directly held by Mr. Lichter."}],"balance_after":12086,"derivative":{"exercise_price":10.73,"expiration_date":"2027-07-19","underlying":"Common Stock","underlying_shares":414},"source":{"system":"sec-edgar","filing":"0001415889-24-023153","document":"form4-09102024_090952.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924023153/form4-09102024_090952.xml","form_type":"4"}},{"id":1410916,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-09-10T21:02:56.000Z","date":"2024-09-09","kind":"exercise","planned":false,"acquired":false,"shares":994,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Immediately exercisable."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"The securities are directly held by Mr. Lichter."}],"balance_after":29006,"derivative":{"exercise_price":17,"expiration_date":"2027-07-19","underlying":"Common Stock","underlying_shares":994},"source":{"system":"sec-edgar","filing":"0001415889-24-023153","document":"form4-09102024_090952.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924023153/form4-09102024_090952.xml","form_type":"4"}},{"id":1410915,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-09-10T21:02:56.000Z","date":"2024-09-09","kind":"sale","planned":false,"acquired":false,"shares":2182,"price":42.33,"value":92364.06,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.33 to $42.39 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"The securities are directly held by Mr. Lichter."}],"balance_after":7000,"source":{"system":"sec-edgar","filing":"0001415889-24-023153","document":"form4-09102024_090952.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924023153/form4-09102024_090952.xml","form_type":"4"}},{"id":1410914,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-09-10T21:02:56.000Z","date":"2024-09-09","kind":"exercise","planned":false,"acquired":true,"shares":277,"price":39.8,"value":11024.6,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"The securities are directly held by Mr. Lichter."}],"balance_after":9182,"source":{"system":"sec-edgar","filing":"0001415889-24-023153","document":"form4-09102024_090952.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924023153/form4-09102024_090952.xml","form_type":"4"}},{"id":1410913,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-09-10T21:02:56.000Z","date":"2024-09-09","kind":"exercise","planned":false,"acquired":true,"shares":414,"price":13.22,"value":5473.08,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"The securities are directly held by Mr. Lichter."}],"balance_after":8905,"source":{"system":"sec-edgar","filing":"0001415889-24-023153","document":"form4-09102024_090952.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924023153/form4-09102024_090952.xml","form_type":"4"}},{"id":1410912,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-09-10T21:02:56.000Z","date":"2024-09-09","kind":"exercise","planned":false,"acquired":true,"shares":414,"price":10.73,"value":4442.22,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"The securities are directly held by Mr. Lichter."}],"balance_after":8491,"source":{"system":"sec-edgar","filing":"0001415889-24-023153","document":"form4-09102024_090952.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924023153/form4-09102024_090952.xml","form_type":"4"}},{"id":1410911,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-09-10T21:02:56.000Z","date":"2024-09-09","kind":"exercise","planned":false,"acquired":true,"shares":994,"price":17,"value":16898.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"The securities are directly held by Mr. Lichter."}],"balance_after":8077,"source":{"system":"sec-edgar","filing":"0001415889-24-023153","document":"form4-09102024_090952.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924023153/form4-09102024_090952.xml","form_type":"4"}},{"id":1410910,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-09-10T21:02:56.000Z","date":"2024-09-06","kind":"sale","planned":false,"acquired":false,"shares":110644,"price":42,"value":4647048.0,"ownership":{"direct":false,"nature":"By Avalon BioVentures SPV I, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by Avalon BioVentures SPV I, LP (\"ABV SPV\"). ABV SPV I GP LLC (\"ABV SPV GP\") is the general partner of ABV SPV and may be deemed to beneficially own the securities held by ABV SPV. Mr. Lichter is a managing member of ABV SPV GP and shares voting and investment power with respect to the securities held by ABV SPV. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":3229374,"source":{"system":"sec-edgar","filing":"0001415889-24-023153","document":"form4-09102024_090952.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924023153/form4-09102024_090952.xml","form_type":"4"}},{"id":1410909,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-09-10T21:02:56.000Z","date":"2024-09-06","kind":"sale","planned":false,"acquired":false,"shares":20991,"price":42,"value":881622.0,"ownership":{"direct":false,"nature":"By Avalon BioVentures I, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by Avalon BioVentures I, LP (\"ABV I\"). Avalon BioVentures GP LLC (\"ABV GP\") is the general partner of ABV I and may be deemed to beneficially own the securities held by ABV I. Mr. Lichter is a managing member of ABV GP and shares voting and investment power with respect to the securities held by ABV I. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":612682,"source":{"system":"sec-edgar","filing":"0001415889-24-023153","document":"form4-09102024_090952.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924023153/form4-09102024_090952.xml","form_type":"4"}},{"id":1410908,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-09-10T21:02:56.000Z","date":"2024-09-06","kind":"sale","planned":false,"acquired":false,"shares":108365,"price":42,"value":4551330.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The securities are directly held by Avalon Ventures XI, L.P. (\"Avalon Ventures\"). Avalon Ventures XI GP, LLC (\"Avalon XI GP\") is the general partner of Avalon Ventures and may be deemed to beneficially own the securities held by Avalon Ventures. Mr. Lichter is a managing member of Avalon XI GP and shares voting and investment power with respect to the securities held by Avalon Ventures. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":3162851,"source":{"system":"sec-edgar","filing":"0001415889-24-023153","document":"form4-09102024_090952.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924023153/form4-09102024_090952.xml","form_type":"4"}},{"id":1490195,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-06-05T23:19:57.000Z","date":"2024-06-03","kind":"sale","planned":false,"acquired":false,"shares":691525,"price":54.75,"value":37860993.75,"ownership":{"direct":false,"nature":"By Avalon BioVentures SPV I, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.75 to $55.07 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are directly held by Avalon BioVentures SPV I, LP (\"ABV SPV\"). ABV SPV I GP LLC (\"ABV SPV GP\") is the general partner of ABV SPV and may be deemed to beneficially own the shares held by ABV SPV. Each of the Reporting Persons disclaims beneficial ownership of these shares except to the extent of its respective pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":3340018,"source":{"system":"sec-edgar","filing":"0001415889-24-015673","document":"form4-06052024_110653.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924015673/form4-06052024_110653.xml","form_type":"4"}},{"id":1490194,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-06-05T23:19:57.000Z","date":"2024-06-03","kind":"sale","planned":false,"acquired":false,"shares":131196,"price":54.75,"value":7182981.0,"ownership":{"direct":false,"nature":"By Avalon BioVentures I, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.75 to $55.07 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are directly held by Avalon BioVentures I, LP (\"ABV I\"). Avalon BioVentures GP LLC (\"ABV GP\") is the general partner of ABV I and may be deemed to beneficially own the shares held by ABV I. Each of the Reporting Persons disclaims beneficial ownership of these shares except to the extent of its respective pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":633673,"source":{"system":"sec-edgar","filing":"0001415889-24-015673","document":"form4-06052024_110653.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924015673/form4-06052024_110653.xml","form_type":"4"}},{"id":1490193,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-06-05T23:19:57.000Z","date":"2024-06-03","kind":"sale","planned":false,"acquired":false,"shares":677279,"price":54.75,"value":37081025.25,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.75 to $55.07 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are directly held by Avalon Ventures XI, L.P. (\"Avalon Ventures\"). Avalon Ventures XI GP, LLC (\"Avalon XI GP\") is the general partner of Avalon Ventures and may be deemed to beneficially own the shares held by Avalon Ventures. Each of the Reporting Persons disclaims beneficial ownership of these shares except to the extent of its respective pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":3271216,"source":{"system":"sec-edgar","filing":"0001415889-24-015673","document":"form4-06052024_110653.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924015673/form4-06052024_110653.xml","form_type":"4"}},{"id":1603470,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":2,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":3,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-03-05T00:31:53.000Z","date":"2024-02-29","kind":"other","planned":false,"acquired":false,"shares":1700,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Avalon BioVentures GP LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F15","text":"Represents a pro rata, in-kind distribution, and not a purchase or sale of securities, by ABV GP to its members without additional consideration."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F14","text":"The shares are held directly by ABV GP.  ABV GP is the general partner of ABV I.  Each of the Reporting Persons disclaims beneficial ownership of these shares except to the extent of its respective pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001415889-24-006428","document":"form4-03052024_120347.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924006428/form4-03052024_120347.xml","form_type":"4"}},{"id":1603469,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":2,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":3,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-03-05T00:31:53.000Z","date":"2024-02-29","kind":"other","planned":false,"acquired":true,"shares":1700,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Avalon BioVentures GP LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F13","text":"Represents receipt of shares in the distribution in kind described in footnote (11)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F14","text":"The shares are held directly by ABV GP.  ABV GP is the general partner of ABV I.  Each of the Reporting Persons disclaims beneficial ownership of these shares except to the extent of its respective pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":1700,"source":{"system":"sec-edgar","filing":"0001415889-24-006428","document":"form4-03052024_120347.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924006428/form4-03052024_120347.xml","form_type":"4"}},{"id":1603468,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":2,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":3,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-03-05T00:31:53.000Z","date":"2024-02-29","kind":"other","planned":false,"acquired":false,"shares":84985,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Avalon BioVentures I, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F11","text":"Represents a pro-rata, in kind distribution, and not a purchase or sale of securities, by Avalon BioVentures I, LP (ABV I) to its general partner and limited partners without additional consideration."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F12","text":"The shares are held directly by ABV I. Avalon BioVentures GP, LLC (ABV GP) is the general partner of ABV I and may be deemed to beneficially own the shares held by ABV I.  Each of the Reporting Persons disclaims beneficial ownership of these shares except to the extent of its respective pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":764869,"source":{"system":"sec-edgar","filing":"0001415889-24-006428","document":"form4-03052024_120347.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924006428/form4-03052024_120347.xml","form_type":"4"}},{"id":1603467,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":2,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":3,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-03-05T00:31:53.000Z","date":"2024-02-29","kind":"other","planned":false,"acquired":false,"shares":31456,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By ABV SPV I GP LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F10","text":"Represents a pro rata, in-kind distribution, and not a purchase or sale of securities, by ABV SPV GP to its members without additional consideration."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"The shares are held directly by ABV SPV GP.  ABV SPV GP  is the general partner of ABV SPV. Each of the Reporting Persons disclaims beneficial ownership of these shares except to the extent of its respective pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001415889-24-006428","document":"form4-03052024_120347.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924006428/form4-03052024_120347.xml","form_type":"4"}},{"id":1603466,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":2,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":3,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-03-05T00:31:53.000Z","date":"2024-02-29","kind":"other","planned":false,"acquired":true,"shares":31456,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By ABV SPV I GP LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F8","text":"Represents receipt of shares in the distribution in kind described in footnote (6)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"The shares are held directly by ABV SPV GP.  ABV SPV GP  is the general partner of ABV SPV. Each of the Reporting Persons disclaims beneficial ownership of these shares except to the extent of its respective pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":31456,"source":{"system":"sec-edgar","filing":"0001415889-24-006428","document":"form4-03052024_120347.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924006428/form4-03052024_120347.xml","form_type":"4"}},{"id":1603465,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":2,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":3,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-03-05T00:31:53.000Z","date":"2024-02-29","kind":"other","planned":false,"acquired":false,"shares":447949,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Avalon BioVentures SPV I, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"Represents a pro rata, in-kind distribution, and not a purchase or sale of securities by Avalon BioVentures SPV I, LP (ABV SPV) to its general partner and limited partners without additional consideration."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The shares are directly held by ABV SPV. ABV SPV I GP LLC (ABV SPV GP) is the general partner of ABV SPV and may be deemed to beneficially own the shares held by ABV SPV. Each of the Reporting Persons disclaims beneficial ownership of these shares except to the extent of its respective pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":4031543,"source":{"system":"sec-edgar","filing":"0001415889-24-006428","document":"form4-03052024_120347.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924006428/form4-03052024_120347.xml","form_type":"4"}},{"id":1603464,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":2,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":3,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-03-05T00:31:53.000Z","date":"2024-02-29","kind":"other","planned":false,"acquired":false,"shares":11388,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Avalon Ventures XI GP LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Represents a pro rata, in-kind distribution, and not a purchase or sale of securities, by Avalon XI GP to its members without additional consideration."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held directly by Avalon XI GP. Avalon XI GP is the general partner of Avalon Ventures. Each of the Reporting Persons disclaims beneficial ownership of these shares except to the extent of its respective pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001415889-24-006428","document":"form4-03052024_120347.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924006428/form4-03052024_120347.xml","form_type":"4"}},{"id":1603463,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":2,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":3,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-03-05T00:31:53.000Z","date":"2024-02-29","kind":"other","planned":false,"acquired":true,"shares":11388,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Avalon Ventures XI GP LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents receipt of shares in the distribution in kind described in footnote (1)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held directly by Avalon XI GP. Avalon XI GP is the general partner of Avalon Ventures. Each of the Reporting Persons disclaims beneficial ownership of these shares except to the extent of its respective pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":11388,"source":{"system":"sec-edgar","filing":"0001415889-24-006428","document":"form4-03052024_120347.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924006428/form4-03052024_120347.xml","form_type":"4"}},{"id":1603462,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":2,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":3,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-03-05T00:31:53.000Z","date":"2024-02-29","kind":"other","planned":false,"acquired":false,"shares":438722,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a pro-rata, in-kind distribution, and not a purchase or sale of securities, by Avalon Ventures XI LP (Avalon Ventures) to its general partner and limited partners without additional consideration."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Avalon Ventures.  Avalon Ventures XI GP, LLC (Avalon XI GP) is the general partner of Avalon Ventures and may be deemed to beneficially own the shares held by Avalon Ventures. Each of the Reporting Persons disclaims beneficial ownership of these shares except to the extent of its respective pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":3948495,"source":{"system":"sec-edgar","filing":"0001415889-24-006428","document":"form4-03052024_120347.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924006428/form4-03052024_120347.xml","form_type":"4"}},{"id":1744144,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":2,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":3,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-11-14T00:11:13.000Z","date":"2023-11-13","kind":"purchase","planned":false,"acquired":true,"shares":849854,"price":5.87,"value":4988642.98,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are directly held by Avalon BioVentures I, LP (ABV I). Avalon BioVentures GP, LLC is a general partner of ABV I and may be deemed to have voting and investment power with respect to the shares held by ABV I and as a result may be deemed to have beneficial ownership of such shares. Jay B. Lichter, Tighe M. Reardon, Sanford J. Madigan and Sergio G. Duron share voting and investment power with respect to the shares held by ABV I. Each of such individuals disclaims beneficial ownership of all shares held by ABV I except to the extent of each such individual's actual pecuniary interest therein, if any."}],"balance_after":849854,"source":{"system":"sec-edgar","filing":"0001209191-23-055083","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000120919123055083/doc4.xml","form_type":"4"}}]}